More encouraging results have been obtained with monalizumab (IPH2201, InnatePharma/AstraZeneca), a humanized anti-NKG2A IgG4 monoclonal antibody (mAb) that has been safely administered to cancer patients [30]. Here, KLRC1 is linked to cancer.